This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
Denali (DNLI) Begins Frontotemporal Dementia-Granulin Study
by Zacks Equity Research
Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.
Denali (DNLI) Q4 Loss Wider Than Expected, Revenues Lag
by Zacks Equity Research
Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.
Seagen (SGEN) Q4 Earnings Miss, Revenues Top Mark, Stock Down
by Zacks Equity Research
Seagen (SGEN) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock falls in after-hours trading.
Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval
by Zacks Equity Research
The FDA grants approval to the new drug application seeking approval for Takeda's (TAK) maribavir for treating post-transplant cytomegalovirus infection.
Denali (DNLI) Stock Up Despite Wider-Than-Expected Q3 Loss
by Zacks Equity Research
Denali (DNLI) announces wider-than-expected loss per share for third-quarter 2021. Nonetheless, its shares rise following the announcement.
Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan
by Zacks Equity Research
Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.
Supernus (SUPN) Seeks Label Expansion for ADHD Drug Qelbree
by Zacks Equity Research
The FDA accepts Supernus' (SUPN) regulatory application seeking label application for Qelbree to include adult patients with ADHD.
Takeda (TAK) Hematology Candidate Fails in Late-Stage Study
by Zacks Equity Research
Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.
Moderna (MRNA) Japan Jabs Resume Amid Safety Risk Per Reports
by Zacks Equity Research
Japan allows use of uncontaminated vials from the same lots of Moderna's (MRNA) COVID-19 vaccine that had some contaminated vials, which led to the temporary halt of vaccination in some parts of the country.
Top Ranked Income Stocks to Buy for August 19th
by Zacks Equity Research
APTS, TAK, CATY, and BSET made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 19, 2021
Novavax's (NVAX) Q1 Loss Widens, Revenues Beat, Shares Down
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.
Amicus' (FOLD) Q1 Loss Wider Than Expected, Sales Up Y/Y
by Zacks Equity Research
Amicus (FOLD) reports a wider Q1 loss and sales miss estimates.
Denali's (DNLI) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Denali (DNLI) posts a wider-than-expected loss in the first quarter of 2021 due to higher R&D costs.
Moving Average Crossover Alert: Takeda Pharmaceutical (TAK)
by Zacks Equity Research
Takeda Pharmaceutical (TAK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Supernus (SUPN) Receives FDA Approval for ADHD Treatment
by Zacks Equity Research
Supernus (SUPN) gets FDA approval for ADHD treatment, Qelbree, in pediatric patients 6 to 17 years of age.
Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Beat on Galafold
by Zacks Equity Research
Amicus (FOLD) reports a wider-than-expected Q4 loss but sales beat estimates.
Denali's (DNLI) Q4 Earnings & Revenues Beat on Biogen Deal
by Zacks Equity Research
Denali (DNLI) posts earnings in the fourth quarter of 2020 due to collaboration revenues from Biogen.
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Seagen (SGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Seagen (SGEN) surpasses estimates for earnings and revenues in the fourth quarter of 2020. The company provides revenues guidance for 2021.
Bristol Myers' (BMY) Application for UC Drug Validated by EMA
by Zacks Equity Research
Bristol Myers' (BMY) MAA for Zeposia for the treatment of adults with moderately to severely active ulcerative colitis gets validated by EMA.
Myovant (MYOV) Up on Collaboration With Pfizer for Relugolix
by Zacks Equity Research
Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.
Karyopharm's (KPTI) Xpovio Gets FDA Nod for Second-Line Myeloma
by Zacks Equity Research
Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in combination with Takeda's Velcade and dexamethasone for treating multiple myeloma in second-line setting.
Novavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates
by Zacks Equity Research
Novavax's (NVAX) bottom line deteriorates year over year in the third quarter of 2020. Revenues fall shy of estimates as well. Stock dips in after-hours trading.